Study Condition(s): Stomach Cancer, Gastroesophageal Junction Cancer (GEJ)

A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Study Alias: JVCW

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02539225 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The main purpose of this study is to evaluate the effectiveness of S-1 and oxaliplatin with or without ramucirumab as first line therapy in participants with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

20+ years

Time Commitment

Your participation could last up to 54 weeks depending on how you and your tumor respond.
  • Participant must have a diagnosis of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, confirmed by histology or cytology; participants with esophageal cancer are not eligible

  • Participants of reproductive potential (men and woman) must agree to use contraception (hormonal or barrier methods) during the study period and at least 6 months after the last dose of study treatment

  • Participant must be willing to provide a blood sample for research purposes

  • Participant must not have human epidermal growth factor receptor 2 (HER2)-positive status

  • Participant must not have known brain metastases, leptomeningeal disease, or uncontrolled spinal cord compression

  • Female participant must not be pregnant or breast feeding. Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to first dose of study treatment

  • Participant must not have any prior malignancies

Where to Participate

35 locations are currently available of 40 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.